WEST LAFAYETTE, Ind., Nov. 26, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that Ron Ellis, Endocyte's president and CEO, will present at the Piper Jaffray 25th Annual Health Care Conference on Tuesday, Dec. 3, at 9 a.m. EST. The conference is being held at The New York Palace Hotel in New York.
A live audio webcast of the Company's presentation can be accessed at http://www.media-server.com/m/p/p42sc3vs or by visiting the Investor Relations section of Endocyte's website at www.endocyte.com. The webcast will be archived shortly after the live event and a replay will be available on the Company's website for 90 days following the conference.
Endocyte is a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company's SMDCs actively target receptors that are expressed or over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly potent drugs into these cells. The companion imaging agents are designed to identify patients whose disease expresses the molecular target of the therapy and who therefore may be more likely to benefit from treatment. For more information, visit http://www.endocyte.com.
CONTACT: Stephanie Ascher, Stern Investor Relations, Inc. (212) 362-1200, email@example.com Martina Schwarzkopf, Ph.D., Russo Partners (212) 845-4292, firstname.lastname@example.org Tony Russo, Ph.D., Russo Partners (212) 845-4251, email@example.comSource:Endocyte, Inc.